- Home
- ASRT vs AVTX Comparison
ASRT vs AVTX Comparison
Compare ASRT & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASRT
- AVTX
- Stock Information
- Founded
- ASRT 1995
- AVTX 2011
- Country
- ASRT United States
- AVTX United States
- Employees
- ASRT N/A
- AVTX N/A
- Industry
- ASRT Biotechnology: Pharmaceutical Preparations
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- ASRT Health Care
- AVTX Health Care
- Exchange
- ASRT Nasdaq
- AVTX Nasdaq
- Market Cap
- ASRT 78.3M
- AVTX 88.4M
- IPO Year
- ASRT 1997
- AVTX 2015
- Fundamental
- Price
- ASRT $0.72
- AVTX $7.42
- Analyst Decision
- ASRT Strong Buy
- AVTX Strong Buy
- Analyst Count
- ASRT 3
- AVTX 5
- Target Price
- ASRT $3.25
- AVTX $36.75
- AVG Volume (30 Days)
- ASRT 329.2K
- AVTX 102.5K
- Earning Date
- ASRT 03-12-2025
- AVTX 05-12-2025
- Dividend Yield
- ASRT N/A
- AVTX N/A
- EPS Growth
- ASRT N/A
- AVTX N/A
- EPS
- ASRT N/A
- AVTX N/A
- Revenue
- ASRT $124,961,000.00
- AVTX $820,000.00
- Revenue This Year
- ASRT N/A
- AVTX N/A
- Revenue Next Year
- ASRT $1.84
- AVTX N/A
- P/E Ratio
- ASRT N/A
- AVTX N/A
- Revenue Growth
- ASRT N/A
- AVTX N/A
- 52 Week Low
- ASRT $0.68
- AVTX $4.35
- 52 Week High
- ASRT $1.80
- AVTX $34.46
- Technical
- Relative Strength Index (RSI)
- ASRT 34.96
- AVTX 49.36
- Support Level
- ASRT $0.74
- AVTX $6.38
- Resistance Level
- ASRT $0.83
- AVTX $8.40
- Average True Range (ATR)
- ASRT 0.04
- AVTX 1.11
- MACD
- ASRT -0.00
- AVTX 0.08
- Stochastic Oscillator
- ASRT 26.90
- AVTX 21.93
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).